Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
- 23 October 2007
- journal article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 8 (11), 975-984
- https://doi.org/10.1016/s1470-2045(07)70285-1
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Rapid vascular regrowth in tumors after reversal of VEGF inhibitionJCI Insight, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical ResultsJournal of Clinical Oncology, 2005
- Biology and Clinical Development of Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2004
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerThe New England Journal of Medicine, 2003
- Effect of Cytokine Therapy on Survival for Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Interpreting the significance of changes in health-related quality-of-life scores.Journal of Clinical Oncology, 1998
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993